Related Experiment Video
Updated: Jan 6, 2026
Author Spotlight: Dendritic Cells Maturation Using Sialidases-Based Enzymatic Treatment of the Cell Surface
Published on: October 20, 2023
ST6GAL1-mediated sialylation inhibits the antitumor immune response in colorectal cancer
Yuanchao Shi1,2, Zhihong Peng3, Zhenzhong Pan4
1Department of General Surgery, The First Affiliated Hospital of Army Medical University, No.30 Gaotanyan Main Street, Shapingba District, Chongqing, 400038, China.
Purpose:
Interferon gamma (IFNG) directly affects the antitumor immune response. ST6-β-galactoside α-2,6-sialyltransferase 1 (ST6GAL1) is also positively correlated with poor prognosis for colorectal cancer (CRC). we performed some works to exploreexplored the underlying mechanism to further understand immune escape in colorectal cancer (CRC).
Methods:
First, we used clinical samples to confirm the relationship between ST6GAL1 and CRC. Afterward, we constructed overexpression/knockdown cell lines and performed bulk RNA sequencing, kinase phosphorylation chip, mass spectrometry, and in vitro and in vivo assays to explore the mechanism regulated by ST6GAL1. Finally, we verified the mechanism by performing immunoprecipitation and immunofluorescence (IF) staining.
Results:
ST6-β-galactoside α-2,6-sialyltransferase 1 (ST6GAL1) expression was negatively correlated with the response to neoadjuvant chemotherapy in patients with CRC and negatively correlated with the sensitivity to IFNG in CRC cell lines. We confirmed that ST6GAL1 overexpression inhibited the infiltration of effector T cells, the levels of IFNG produced by CD8+ T cells and CD4+ T cells decreased, and the levels of granzyme B produced by effector cells decreased in animal models. The results of in vitro assays and phosphorylation chip detection revealed that ST6GAL1 inhibited IFNG receptor 1 (IFNGR1) phosphorylation, thus decreasing the activation of the JAK1/STAT1 signaling pathway. Through immunoprecipitation assays and mass spectrometry, we found that ST6GAL1 can sialylate BICD cargo adaptor 2 (BICD2), thereby affecting the interaction between BICD2 and IFNGR1 to ultimately inhibit the phosphorylation of IFNGR1 and promote immune escape.
Conclusions:
Our results confirmed that ST6GAL1 decreases the sensitivity of tumor cells to IFNG. This study describes a novel mechanism by which ST6GAL1 promotes the immune escape and malignant progression of CRC.
Insights
ST6GAL1 hinders the antitumor immune response in colorectal cancer (CRC) by reducing interferon gamma (IFNG) sensitivity. This mechanism promotes CRC immune escape and progression.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Interferon gamma (IFNG) is crucial for antitumor immunity.
- ST6-β-galactoside α-2,6-sialyltransferase 1 (ST6GAL1) is linked to poor prognosis in colorectal cancer (CRC).
- Understanding the mechanism of immune escape in CRC is critical.
Purpose of the Study:
- To investigate the role of ST6GAL1 in colorectal cancer (CRC) immune escape.
- To elucidate the underlying molecular mechanism by which ST6GAL1 affects the antitumor immune response.
Main Methods:
- Analysis of clinical CRC samples.
- Construction of ST6GAL1 overexpression/knockdown cell lines.
- Bulk RNA sequencing, kinase phosphorylation chip, mass spectrometry, in vitro/in vivo assays, immunoprecipitation, and immunofluorescence staining.
Main Results:
- ST6GAL1 expression negatively correlates with chemotherapy response and IFNG sensitivity in CRC.
- ST6GAL1 overexpression reduces effector T cell infiltration, IFNG production, and granzyme B levels.
- ST6GAL1 inhibits IFNGR1 phosphorylation by sialylating BICD2, suppressing the JAK1/STAT1 pathway.
Conclusions:
- ST6GAL1 decreases tumor cell sensitivity to IFNG, promoting CRC immune escape.
- A novel mechanism involving ST6GAL1, BICD2, and IFNGR1 in CRC progression is identified.
